-诺和力与其它肠促胰素治疗药物的对比演示文稿.ppt

诺和力?与其它肠促胰素治疗药物的对比 诺和力?与人GLP-1同源性高，抗体产生少 * * * * * Data at week 52: Liraglutide 1.2 mg: 74.2% Liraglutide 1.8 mg: 76.0% Sitagliptin: 52.8 % * Estimated treatment difference vs. sitagliptin 1.2 mg 1.8 mg Odds ratio 2.75 4.50 95% CI [1.78, 4.25] [2.90, 6.97] p-value 0.0001 0.0001 * * * * The improvement in overall treatment satisfaction from baseline to 52 weeks, measured as the increase in DTSQ scores, was significantly greater with liraglutide 1.8 mg than sitagliptin (4.3±0.5 vs. 3.0±0.5, respectively; p=0.03), whereas the difference between liraglutide 1.2 mg and sitagliptin